Loading…
Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.
Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.
Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak.
In one line: China's answer to a viral-vector vaccine developer like J&J's Janssen unit.
Moat: narrow (IP / patents, regulatory licence). Proprietary adenovirus-vector platform and one of few Chinese firms with an approved viral-vector vaccine.
Headquarters: Tianjin, China · Employees: 1,134
Size CanSino Biologics (688185.SS) is a China Health Care company (Biotechnology) with a market value of $1.73B, the 1431st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥74.20 on 6 Nov 2026.
Performance Over six months the shares gained 20.6%, against -2.2% for the median peer and -16.4% for the China market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 29.9% over the last twelve months (peer median +15.9%); the operating margin is -4.2% (peer median -46.1%).
Valuation It trades at 245.0× forward earnings against a peer median of 51.3× (most expensive of 6).
Capital Return on invested capital runs 9.7 points below its cost of capital (11.3% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.26B | CN¥1.07B | CN¥836M | CN¥349M | CN¥1.03B |
| Revenue growth | — | +28% | +139% | -66% | — |
| Gross profit | CN¥1.03B | CN¥729M | CN¥517M | -CN¥21.8M | CN¥536M |
| EBITDA | n/a | CN¥65.5M | -CN¥185M | -CN¥1.54B | -CN¥1.32B |
| Net income | CN¥29.7M | CN¥27.9M | -CN¥379M | -CN¥1.48B | -CN¥909M |
| Free cash flow | -CN¥60.9M | -CN¥108M | -CN¥536M | -CN¥1.47B | -CN¥2.82B |
| Capital expenditure | CN¥159M | CN¥244M | CN¥458M | CN¥610M | CN¥1.08B |
| Total debt | CN¥930M | CN¥1.29B | CN¥2.02B | CN¥2.71B | CN¥2.73B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CanSino Biologics 688185.SS | $1.73B | +21% | +30% | -4% | 245.0× | n/a |
| Walvax Biotechnology 300142.SZ | $2.71B | -12% | -23% | 5% | 381.7× | 31.3% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Chongqing Zhifei Biological Products 300122.SZ | $5.35B | -2% | -28% | -210% | n/a | -6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688185.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.5% | -8.8% | 4th lowest of 20 |
| 6-month return | +20.6% | -2.2% | 5th highest of 19 |
| Distance from 52-week high | -31.3% | -38.6% | 7th highest of 20 |
| Revenue growth (TTM) | +29.9% | +15.9% | 8th highest of 20 |
| Operating margin | -4.2% | -46.1% | 6th highest of 20 |
| Forward P/E | 245.0× | 51.3× | most expensive of 6 |
| ROIC minus cost of capital | -9.7 pp | -17.3 pp | 6th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CanSino Biologics 688185.SS | China | $1.73B | +21% | +30% | -4% | 245.0× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 166.7× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 29.7× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | n/a | -19.0% | +36.4% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 51.3× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 51.5× | n/a | n/a |